baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Heidelberg Pharma AG/ DE000A11QVV0 /

06/06/2024 07:57:06	Chg. 0.0000	Volume	Bid11:01:46	Ask11:01:46	Market Capitalization	Dividend Y.	P/E Ratio
2.9000EUR	0.00%	- Turnover: -	2.8700Bid Size: 1,050	2.9400Ask Size: 1,050	97.74 mill.EUR	0.00%	-

GlobeNewswire 26/05/2021 Immatics Announces Changes to its Board of Directors

GlobeNewswire 11/03/2020 RedHill Biopharma Provides Update on Opaganib (Yeliva®)

GlobeNewswire 19/10/2018 ADC Contract Manufacturing Market, 2030

GlobeNewswire 17/07/2018 APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer

GlobeNewswire 16/11/2017 Antibody Drug Conjugates Market, 2030 - Market is Anticipated to Grow at a CAGR to 19.4%

GlobeNewswire 24/08/2017 Global Cell Line Development Services Market, 2027

GlobeNewswire 06/07/2017 Biopharmaceutical Contract Manufacturing Market, 2027

GlobeNewswire 12/11/2007 HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE

GlobeNewswire 21/05/2007 Clinical effectiveness and tolerability of Fosalvudine (HIV) confirmed

GlobeNewswire 17/05/2007 Fosfluridine Tidoxil shows effectiveness in Actinic Keratosis

GlobeNewswire 05/02/2007 Recruitment completed for phase IIa trial with fosfluridine tidoxil in actinic keratosis

GlobeNewswire 10/01/2007 Heidelberg Pharma becomes a Corporation

GlobeNewswire 09/10/2006 Start of clinical phase II with Fosalvudine for treatment of HIV-infected patients

GlobeNewswire 02/10/2006 Heidelberg Pharma raises 16 million EUR (20 million USD) in series B-Round

Heidelberg Pharma AG/ DE000A11QVV0 /

If you wish to receive reply to your feedback, please provide your email address.